Joseph Bargellini, MD
Radiation Oncology · New Milford, CTNPI 1619062494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.
Across 26 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$131
- Pfizer$56
- Regeneron Healthcare Solutions, Inc.$48
- Novocure Inc.$47
- Progenics Pharmaceuticals, Inc.$45
- AMAG Pharmaceuticals, Inc.$37
- plus $201 from 9 others
What the payments were for
- Food & beverage$51591%
- Education$499%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $131 |
| Pfizer | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Novocure Inc. | 2 | $47 |
| Progenics Pharmaceuticals, Inc. | 2 | $45 |
| AMAG Pharmaceuticals, Inc. | 2 | $37 |
| Vertex | 1 | $35 |
| Merck | 1 | $30 |
| Gilead | 1 | $26 |
| Teleflex LLC | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Bayer | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
How this compares
$564 in reported general payments places this provider in the 60th percentile of 74 radiation oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 41 | $190,602 |
| OrgovyxRelugolix | 11 | $27,969 |
| Mometasone Furoate | 54 | $829 |
| Tamsulosin Hcl | 78 | $806 |
| Methocarbamol | 14 | $181 |
| Prednisone | 44 | $132 |
| Ciprofloxacin Hcl | 26 | $123 |
| Gabapentin | 15 | $115 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in New Milford
- Roy DeckerNew Haven$111K
- Ranjit BindraNew Haven$64K
- Henry ParkNew Haven$25K
- Zain HusainNew Haven$14K
- Steven OhStamford$14K
- Helaine BertschHartford$13K
- Andrew SalnerHartford$11K
- David ByunHartford$5K
- Deborah FangBridgeport$4K
- Meena Savur MoranNew Haven$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.